The presence of functional TILs is critical to antitumor immunity, and response to ICI largely rests on the presence of a TIME with increased TILs, as well as increased expression of PD-(L)1 in both tumor and immune cells, especially early during treatment [19,45,46,47,48]. This evidence concerns the gene CD274 and neoplasm.